Global Bio-CDMO market projected to reach USD 59.05 billion by 2030

The global biopharmaceutical Contract Development and Manufacturing Organization (Bio-CDMO) market is expected to reach USD 59.05 billion by 2030, growing at a compound annual growth rate of 12.7 percent. This growth is driven by increasing demand for biologics, such as monoclonal antibodies, recombinant proteins, and gene therapies, as well as the cost-effectiveness of outsourcing drug development and manufacturing processes.

Key industry players include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, and Boehringer Ingelheim. In 2023, the top five manufacturers held approximately 49.0 percent of the market share. The industry structure reflects high capital intensity, significant regulatory qualification requirements, and the necessity of validated track records for commercial supply agreements.

In response to industry needs, there is an increasing focus on sustainability within the CDMO sector. Sustainable practices involve integrating environmental performance, resilient supply chains, and responsible governance into facility design and resource management. Efforts to reduce environmental impact include optimizing energy use in building systems like heating, cooling, and ventilation, as well as improving water use and reducing material losses.